3 Hrs
Source:
الصحة والعلوم الشرق الأوسط
Morning immunotherapy linked to longer survival
A comprehensive study revealed that receiving cancer immunotherapy in the morning may double the chances of survival compared to receiving it in the afternoon. The study, which involved 2,631 patients with advanced cancers, highlighted clear differences in survival rates between those who received treatment in the morning and those in the evening. On average, melanoma patients who received treatment in the morning survived for 43.1 months, compared to 21.1 months for those treated in the afternoon; for lung cancer patients, the survival was 24.4 months versus 11.8 months; and for kidney cancer patients, 39.2 months versus 26.1 months. It is believed that this variation is due to the body's circadian rhythms, which influence the activity of immune cells. However, researchers continue their studies to confirm whether timing is the primary factor, and this could potentially lead to adjustments in treatment schedules in the future to improve outcomes.
Size: 120%Text Size
Notice: This Is an AI-Generated Summary
Comments (0)